Acute Myelogenous Leukemia

Oncology
26
Pipeline Programs
18
Companies
22
Clinical Trials
2 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
13
4
7
1
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
360%
ADC
240%
+ 21 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
DECITABINEApproved
decitabine
Unknown Company
Nucleoside Metabolic Inhibitor [EPC]intravenous2020

Competitive Landscape

18 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
4 programs
3
1
DecitabinePhase 2/31 trial
DecitabinePhase 21 trial
DecitabinePhase 21 trial
OndansetronPhase 21 trial
Active Trials
NCT00760084Completed10Est. Feb 2008
NCT00882102Completed43Est. Aug 2012
NCT01031498Completed150Est. Sep 2009
+1 more trials
Pfizer
PfizerNEW YORK, NY
3 programs
2
1
MylotargPhase 21 trial
Gemtuzumab OzogamicinPhase 1ADC1 trial
HMAPhase 11 trial
Active Trials
NCT03904251Terminated13Est. Oct 2023
NCT01902329Completed195Est. Dec 2017
NCT00044733Completed38Est. Sep 2004
BioLineRx
BioLineRxIsrael - Modi’in
1 program
1
BL-8040Phase 21 trial
Active Trials
NCT02639559CompletedEst. Apr 2023
Race Oncology
Race OncologyAustralia - Sydney
1 program
1
BisantrenePhase 21 trial
Active Trials
NCT03820908CompletedEst. Jul 2020
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
PentostatinPhase 2Small Molecule1 trial
Active Trials
NCT00571662CompletedEst. Dec 2008
Genentech
GenentechCA - Oceanside
2 programs
1
1
VenetoclaxPhase 1/2
PosaconazolePhase 1Small Molecule
Sanofi
SanofiPARIS, France
2 programs
1
1
PlerixaforPhase 1/21 trial
SAR103168Phase 11 trial
Active Trials
NCT00981240Completed30Est. Feb 2012
NCT01160354Terminated22Est. Mar 2016
Curis
CurisMA - Lexington
1 program
1
EmavusertibPhase 1/2Small Molecule1 trial
Active Trials
NCT04278768RecruitingEst. Apr 2026
Sellas Life Sciences Group
1 program
1
galinpepimut-SPhase 1/2
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
2 programs
2
CPX-351Phase 11 trial
Gemtuzumab OzogamicinPhase 1ADC
Active Trials
NCT00875693Completed47Est. Dec 2017
Bristol Myers Squibb
1 program
1
BMS-936564Phase 11 trial
Active Trials
NCT01120457Completed96Est. Nov 2014
Fate Therapeutics
Fate TherapeuticsSAN DIEGO, CA
1 program
1
FT516Phase 11 trial
Active Trials
NCT04023071TerminatedEst. Oct 2023
InnoCare
InnoCareChina - Beijing
1 program
1
ICP-248Phase 11 trial
Active Trials
NCT06656494Recruiting266Est. Jan 2028
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
1 program
1
KW-2449Phase 11 trial
Active Trials
NCT00346632Terminated37Est. Apr 2008
Takeda
TakedaTOKYO, Japan
1 program
1
MLN4924Phase 11 trial
Active Trials
NCT01814826Completed64Est. Apr 2018
Angel Pharmaceuticals
Angel PharmaceuticalsChina - Zhejiang
1 program
1
TranylcyprominePhase 11 trial
Active Trials
NCT02273102CompletedEst. Jul 2020
Xencor
XencorPASADENA, CA
1 program
1
XmAb14045Phase 11 trial
Active Trials
NCT02730312CompletedEst. Sep 2021
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
3 TeslaN/A1 trial
Active Trials
NCT01537159Completed23Est. Dec 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
EisaiDecitabine
Race OncologyBisantrene
BioLineRxBL-8040
EisaiDecitabine
EisaiOndansetron
EisaiDecitabine
Astex PharmaceuticalsPentostatin
PfizerMylotarg
CurisEmavusertib
SanofiPlerixafor
InnoCareICP-248
Fate TherapeuticsFT516
PfizerGemtuzumab Ozogamicin
XencorXmAb14045
Angel PharmaceuticalsTranylcypromine

Showing 15 of 22 trials with date data

Clinical Trials (22)

Total enrollment: 1,084 patients across 22 trials

NCT00398983EisaiDecitabine

Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)

Start: Aug 2006Est. completion: May 201250 patients
Phase 2/3Completed
NCT03820908Race OncologyBisantrene

Bisantrene for Relapsed /Refractory AML

Start: Jul 2019Est. completion: Jul 2020
Phase 2Completed
NCT02639559BioLineRxBL-8040

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Start: Mar 2016Est. completion: Apr 2023
Phase 2Completed
NCT00882102EisaiDecitabine

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Start: Apr 2009Est. completion: Aug 201243 patients
Phase 2Completed
NCT01031498EisaiOndansetron

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

Start: Sep 2005Est. completion: Sep 2009150 patients
Phase 2Completed
NCT00760084EisaiDecitabine

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Start: Jul 2005Est. completion: Feb 200810 patients
Phase 2Completed
NCT00571662Astex PharmaceuticalsPentostatin

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Start: Dec 2000Est. completion: Dec 2008
Phase 2Completed
NCT00044733PfizerMylotarg

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

Start: Mar 2000Est. completion: Sep 200438 patients
Phase 2Completed
NCT04278768CurisEmavusertib

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Start: Jul 2020Est. completion: Apr 2026
Phase 1/2Recruiting
NCT01160354SanofiPlerixafor

Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)

Start: Aug 2010Est. completion: Mar 201622 patients
Phase 1/2Terminated
NCT06656494InnoCareICP-248

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Start: Dec 2024Est. completion: Jan 2028266 patients
Phase 1Recruiting
NCT04023071Fate TherapeuticsFT516

FT516 in Subjects With Advanced Hematologic Malignancies

Start: Oct 2019Est. completion: Oct 2023
Phase 1Terminated
NCT03904251PfizerGemtuzumab Ozogamicin

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Start: Jul 2019Est. completion: Oct 202313 patients
Phase 1Terminated
NCT02730312XencorXmAb14045

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Start: Aug 2016Est. completion: Sep 2021
Phase 1Completed
NCT02273102Angel PharmaceuticalsTranylcypromine

Study of TCP-ATRA for Adult Patients With AML and MDS

Start: Mar 2015Est. completion: Jul 2020
Phase 1Completed
NCT01902329PfizerHMA

A Safety Study of SGN-CD33A in AML Patients

Start: Jul 2013Est. completion: Dec 2017195 patients
Phase 1Completed
NCT01814826TakedaMLN4924

Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

Start: Apr 2013Est. completion: Apr 201864 patients
Phase 1Completed
NCT01120457Bristol Myers SquibbBMS-936564

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Start: Aug 2010Est. completion: Nov 201496 patients
Phase 1Completed
NCT00981240SanofiSAR103168

Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes

Start: Sep 2009Est. completion: Feb 201230 patients
Phase 1Completed
NCT00875693Jazz PharmaceuticalsCPX-351

A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)

Start: Jun 2009Est. completion: Dec 201747 patients
Phase 1Completed
NCT00346632Kyowa Hakko KirinKW-2449

An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

Start: Jun 2006Est. completion: Apr 200837 patients
Phase 1Terminated
NCT01537159Knight Therapeutics3 Tesla

MRI Assessment of Leukemia Response to Therapy

Start: May 2012Est. completion: Dec 201823 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 1,084 patients
18 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)